title: Problems in the management of urea cycle disorders.
abstract: Several recent reviews describe the management of urea cycle disorders. There is much agreement on diet, alternative pathway therapy, maintenance of arginine and ornithine levels in acute and chronic management, sick-day regimens, and some aspects of monitoring. However, differences remain in several areas, and physicians at most treatment centers have relatively little experience, because these disorders are rare. Early suspicion of the diagnosis of a urea cycle disorder, and prompt referral to a tertiary center is vital. Drug treatment using chronic administration of sodium benzoate has been abandoned by some centers, but the acceptability of phenylbutyrate is an issue for many patients. Using citrulline chronically is not always successful in recommended doses, and may result in an arginine level too low for maximum control. Appetite and nutrition problems are common. One major concern is the early identification and management of chronic catabolism, theoretically easy, but hard in practice. Biochemical measurement problems complicate monitoring, and there are disagreements about the optimum way of identifying OTC carriers. It is not always clear whom to treat. Within a kindred with an early-onset phenotype, an asymptomatic newborn girl may need treatment for some undetermined time, but target values for monitoring are not clear. In late-onset phenotypes, management of asymptomatic males identified by family screening is also difficult. Most centers do not have sufficient cases to solve these conundrums, some of which require further multicenter study. This paper examines the recommendations of a consensus conference on management, outlines some remaining problems, and incorporates in the text the points raised in open discussion during a session of a symposium held in Sydney in 2003 entitled "New Developments in Urea Cycle Disorders."
authors.affiliation: The Children's Hospital at Westmead and the Discipline of Paediatrics, University of Sydney, Sydney, Australia. bridgetw@chw.edu.au
authors.forename: Bridget
authors.initials: B
authors.lastname: Wilcken
mesh_terms: D000328:Adult; D000641:Ammonia / Q000097:blood; D005260:Female; D006801:Humans; D008297:Male; D008661:Metabolism, Inborn Errors / Q000097:blood / Q000175:diagnosis / Q000628:therapy*; D020163:Ornithine Carbamoyltransferase Deficiency Disease / Q000097:blood / Q000175:diagnosis / Q000628:therapy; D016896:Treatment Outcome; D014508:Urea / Q000378:metabolism*
chemical_list: D000641:Ammonia; D014508:Urea